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Abstract
The UK incidence of pancreatic ductal adenocarcinoma is 9 per 100,000 population,
and biliary tract cancer occurs at a rate of 1–2 per 100,000. The incidence of both
cancers is increasing annually and these tumours continue to be diagnosed late and at
an advanced stage, limiting options for curative treatment. Population-based screening
programmes do not exist for these cancers, and diagnosis currently is dependent on
symptom recognition, but often symptoms are not present until the disease is
advanced. Recently, a number of promising blood and urine biomarkers have been
described for pancreaticobiliary malignancy and are summarised in this review. Novel
endoscopic techniques such as single-operator cholangioscopy and confocal
endomicroscopy have been used in some centres to enhance standard endoscopic
diagnostic techniques and are also evaluated in this review.
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Introduction
In the UK, pancreatic ductal adenocarcinoma (PDAC) is the 
10th commonest cancer and has an incidence of 9 per 100,000 
population1, and biliary tract cancer (BTC) (including intra- and 
extra-hepatic cholangiocarcinoma and gallbladder cancer) has 
an incidence of 1–2 cases per 100,000 population2. Long-term 
survival is poor; 5-year survival is less than 4% for both tumours3,4. 
Often these tumours are diagnosed late, when patients have 
advanced disease and curative surgical resection is no longer 
possible.
Globally the highest incidence of PDAC is seen in Northern 
Europe and North America5, where the rates are 3 to 4 times 
higher than in tropical countries6. Overall incidence is increasing5, 
and as most tumours are sporadic, this rising incidence is attrib-
uted to differences in lifestyles and exposure to environmental 
risk factors7, such as smoking8–15, diabetes mellitus, chronic 
pancreatitis1,15,16 and obesity17.
In BTC, the variations in incidence seen globally are even 
more pronounced; and the highest incidence is in northeastern 
Thailand (96 per 100,000 men)18, which has a population with high 
levels of chronic typhoid and infestation of liver fluke (Clonorchis 
sinensis and Opisthorchis viverinni)18. Other BTC risk factors 
seen in all populations include older age18, primary sclerosing 
cholangitis19, intraductal stones and rare biliary cystic diseases20. 
Inflammatory bowel disease, chronic viral hepatitis, cirrhosis, 
smoking, diabetes, obesity and excess alcohol consumption may 
also increase the risk of BTC20–22.
Despite improved diagnostic techniques, detecting pancreati-
cobiliary malignancy remains a significant clinical challenge. 
A common presentation of these tumours is a biliary stricture 
with or without a mass lesion. The differential of an indeterminate 
biliary stricture is broad, and often the associated symptoms and 
radiological findings overlap between benign and malignant 
conditions, often making differentiation—particularly between 
cancer, primary sclerosing cholangitis and IgG4-related 
disease—impossible without further investigations, typically by 
endoscopic retrograde cholangiopancreatography (ERCP) or endo-
scopic ultrasound (EUS)23–25. However, biliary brush cytology 
is also an imperfect test, although specificity is high (96–100%), 
sensitivity for malignancy remains low (9–57%) and in early 
disease when tumours are small, sensitivities are even lower26,27. 
Therefore, patients frequently require multiple procedures to obtain 
a final diagnosis28–30.
So there has been growing interest in the development of simple 
tests to streamline the diagnosis to pancreaticobiliary malignancy 
and guide appropriate and timely therapy for patients. Identify-
ing better diagnostic tools for PDAC and BTC would also make 
screening and surveillance possible, particularly in high-risk 
populations4,8,31. This would enable the detection of tumours at 
an earlier stage when curative resection is possible, leading to 
substantial improvements in survival32. This review provides an 
overview of the latest innovations in diagnostic biomarkers and 
endoscopic techniques for pancreaticobiliary malignancy.
Methods
We performed a systematic review of the literature by using 
PubMed, EMBASE and the Cochrane Library. The search was 
limited to studies published in the English language between 
January 2013 and March 2017. Medical Subject Headings (MeSH) 
terms were decided by a consensus of the authors and included 
“pancreatic cancer” or “cholangiocarcinoma” and “biomarker”. 
The search was restricted to title, abstract and keywords. 
Articles that described outcomes for fewer than five patients 
were excluded. Case reports, abstracts and reviews were excluded. 
All references were screened for potentially relevant studies not 
identified in the initial literature search.
The following variables were extracted for each report when 
available: number of malignant and benign cases, sensitivity, 
specificity and area under the curve (AUC). One hundred ten 
articles were included in the final review.
Biomarkers
1. Serum biomarkers and blood tests
Carbohydrate antigen (CA) 19-9 is the most widely used 
tumour marker in pancreaticobiliary malignancy. Overall sensi-
tivity (78–89%) and specificity (67–87%) are low, and in around 
7% of the population who lack the Lewis (a) antigen, CA19-9 
will remain negative33. In small tumours, sensitivity decreases 
further. The marker can also be elevated in a number of other 
malignant diseases (for example, gastric adenocarcinoma) 
and benign diseases, particularly those causing jaundice (for 
example, primary biliary cirrhosis, cholestasis and cholangitis), 
and in smokers34. In addition, variation has been reported 
among commercially available assays, which may impact on 
interpretation35. Therefore, to improve the sensitivity of the marker 
in current clinical practice, it is always interpreted in the context 
of cross-sectional imaging findings33.
Other commercially available tumour markers that have a role 
in diagnosing pancreaticobiliary cancer include carcinoembry-
onic antigen (CEA) and CA125. CEA is a glycosyl phosphatidyl 
inositol cell surface-anchored glycoprotein that is involved in 
cell adhesion. When elevated, it is highly suggestive of color-
ectal cancer, but it is also increased in about a third of patients 
with BTC36–38. CA125 is a protein encoded by the MUC16 gene 
and is a large membrane-associated glycoprotein with a single 
transmembrane domain. When elevated, it is suggestive of 
ovarian cancer, but it is also increased in about 40–50% of patients 
with pancreaticobiliary malignancy, particularly when there is 
peritoneal involvement38.
Owing to the limitations of existing biomarkers, over the last 
few years several studies have evaluated various combinations of 
biomarkers to supplement or ultimately replace existing biomar-
kers. Biomarker panels using combinations of markers, often 
including CA19-9, have been particularly successful in detect-
ing small tumours and early disease. Validation studies have also 
shown that these markers can differentiate PDAC from relevant 
benign conditions and in some cases detect tumours up to 1 year 
prior to diagnosis with a specificity of 95% and a sensitivity of 
68%7 (Table 1 and Table 2).
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Table 1. Serum protein biomarkers for biliary tract cancer, 2013–2017.
Author (year) Biomarker/ 
Combination 
(serum)
Biliary tract 
cancer, number
Benign lesion/ 
cholangitis, 
number
Healthy 
volunteers, 
number
Sensitivity Specificity Area 
under the 
curve
Single biomarkers
Han et al. (2013)84 HDGF 83 - 51 66% 88% 0.81
Ruzzenente et al. (2014)85 MUC5AC 49 23 16 - - 0.91
Voigtlander et al. (2014)86 Angpt-2 56 111 - 74% 94% 0.85
Lumachi et al. (2014)87 CA 19-9 24 25 - 74% 82% -
Wang et al. (2014)88 CA 19-9 78 78 78 72% 96% -
Lumachi et al. (2014)87 CEA 24 25 - 52% 55% -
Wang et al. (2014)88 CEA 78 78 78 11% 97% -
Wang et al. (2014)88 CA 125 78 78 78 45% 96% -
Lumachi et al. (2014)87 CYFRA 21-1 24 25 - 76% 79% -
Liu et al. (2015)89 VEGF-C 31 10 10 71% 80% 0.79
Liu et al. (2015)89 VEGF-D 31 10 10 74% 85% 0.84
Huang et al. (2015)90 CYFRA 21-1 134 52 - 75% 85% -
Lumachi et al. (2014)87 MMP7 24 25 - 78% 77% -
Nigam et al. (2014)91 Survivin 39 (gallbladder 
cancer)
30 25 81% 80% -
Rucksaken et al. (2014)92 HSP70 31 12 23 94% 74% 0.92
Rucksaken et al. (2014)92 ENO1 31 - 23 81% 78% 0.86
Rucksaken et al. (2014)92 RNH1 31 - 23 94% 67% 0.84
Wang et al. (2014)88 CA242 78 78 78 64% 99% -
Ince et al. (2014)93 VEGFR3 96 129 - 48% 82% 0.62
Ince et al. (2014)93 TAC 96 129 - 61% 60% 0.60
Rucksaken et al. (2017)94 ORM2 70 46 20 92% 74% -
Rose et al. (2016)95 CEACAM6 41 42 - 87.5% 69% 0.74
Jiao et al. (2014)96 Nucleosides 202 (gallbladder 
cancer)
203 205 91% 96% -
Biomarker combinations
Lumachi et al. (2014)87 CEA + CA19-9 + 
CYFRA 21-1 + MMP7
24 25 - 92% 96%
In pancreaticobiliary malignancy and PDAC in particular, 
metastatic disease occurs at a very early stage in tumour 
development. This is demonstrated by the fact that patients who 
underwent resection of small primary tumours (<2 cm) with no 
clinical evidence of metastatic disease had a 5-year survival after 
pancreatectomy of less than 18% owing to recurrent metastatic 
disease39. Tumour development is driven by a series of cumu-
lative genetic abnormalities; therefore, genetic and epigenetic 
changes have been explored as diagnostic targets in circulating 
tumour cells, cell-free DNA (cfDNA) and non-coding RNA 
(Table 3–Table 5). Owing to the position and composition of 
pancreaticobiliary tumours, tissue samples are frequently acel-
lular, making diagnostics challenging. Recently, the utility of 
next-generation sequencing was explored as a technique that allows 
the detection of low-abundance mutations and abnormalities in 
small amounts of material40. Changes in the metabalome are also 
being explored as a potential diagnostic tool in pancreaticobiliary 
malignancy41.
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Table 2. Serum protein biomarkers for pancreatic cancer, 2012–2017.
Author (year) Biomarker/ 
Combination 
(serum)
PDAC, number Benign 
controls, 
number
Healthy 
volunteers, 
number
Sensitivity Specificity Area 
under 
the 
curve
Single biomarkers
Sogawa et al. (2016)97 C4BPA 52 20 40 67% 95% 0.860
Rychlikova et al. (2016)98 Osteopontin 64 71 48 - - -
Lin et al. (2016)99 APOA-I 78 - 36 96% 72.2% 0.880
Lin et al. (2016)99 TF 78 - 36 75% 72.8% 0.760
Guo et al. (2016)100 Dysbindin 250 80 150 81.9% 84.7% 0.849
Han et al. (2015)101 Dickkopf-1 140 - 92 89.3% 79.3% 0.919
Qu et al. (2015)102 DCLK1 74 74 - - - 0.740
Dong et al. (2015)103 Survivin 80 - 80 - - -
Gebauer et al. (2014)104 EpCAM 66 43 104 66.7% 77.5% -
Wang et al. (2014)105 MIC-1 807 165 500 65.8% 96.4% 0.935
Kendrick et al. (2014)106 IGFBP2 84 40 84 22% 95% 0.655
Kendrick et al. (2014)106 MSLN 84 40 84 17% 95% 0.668
Kang et al. (2014)107 COL6A3 44 46 30 - - 0.975
Willumsen et al. (2013)108 C1M 15 - 33 - - 0.830
Willumsen et al. (2013)108 C3M 15 - 33 - - 0.880
Willumsen et al. (2013)108 C4M 15 - 33 - - 0.940
Willumsen et al. (2013)108 C4M12a1 15 - 33 - - 0.890
Falco et al. (2013)109 BAG3 52 - 44 75% 75% 0.770
Falco et al. (2013)109 BAG3 52 17 (chronic 
pancreatitis)
- 81% 77% 0.810
Chen et al. (2013)110 TTR 40 - 40 91% 47% 0.730
Gold et al. (2013)111 PAM4 298 - 79 76% 96% -
Gold et al. (2013)111 PAM4 298 120 - - - 0.890
Poruk et al. (2013)112 OPN 86 48 86 - - 0.720
Poruk et al. (2013)112 TIMP-1 86 48 86 - - 0.770
Lee et al. (2014)113 CA 19-9 41 12 44 80.4% 70% 0.833
Lee et al. (2014)113 Human 
complement 
factor B (CFB)
41 12 44 73.1% 97.9% 0.958
Mixed cohorts
Ince et al. (2014)93 CEA 96 (41 PDAC +25 BTC) 129 - 42.7% 89.9% 0.713
Ince et al. (2014)93 CA19-9 96 (41 PDAC +25 BTC) 129 - 49% 84.5% 0.701
Ince et al. (2014)93 VEGFR3 96 (41 PDAC +25 BTC) 129 - 48.4% 82.9% 0.622
Ince et al. (2014)93 Total antioxidant 
capacity
96 (41 PDAC +25 BTC) 129 - 61.1% 60.5% 0.602
Abdel-Razik et al. (2016)114 IGF-1 47 (25 PDAC + 18 BTC) 62 - 62% 51% 0.605
Abdel-Razik et al. (2016)114 VEGF 47 (25 PDAC + 18 BTC) 62 - 58.3% 57.3% 0.544
Biomarker combinations
Chen et al. (2013)110 TTR + CA19-9 40 - 40 81% 85% 0.910
Lee et al. (2014)113 CA19-9 + CFB 41 12 44 90.1% 97.2% 0.986
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Author (year) Biomarker/ 
Combination 
(serum)
PDAC, number Benign 
controls, 
number
Healthy 
volunteers, 
number
Sensitivity Specificity Area 
under 
the 
curve
Sogawa et al. (2016)97 C4BPA + CA19-9 52 20 40 86% 80% 0.930
Makawita et al. (2013)115 CA19-9 + REG1B 100 - 92 - - 0.880
Makawita et al. (2013)115 CA19-9 + SYCN 
+ REG1B
100 - 92 - - 0.870
Willumsen et al. (2013)108 C1M + C3M + 
C4M + C4M12a1
15 - 33 - - 0.990
Shaw et al. (2014)116 IL10 + IL6 + 
PDGF + Ca19-9
84 45 (benign) - 93% 58% 0.840
Shaw et al. (2014)116 IL8 + IL6 +  
IL-10 + Ca19-9
84 32 (chronic 
pancreatitis)
- 75% 91% 0.880
Shaw et al. (2014)116 IL8 + IL1b +  
Ca 19-9
127 - 45 94% 100% 0.857
Brand et al. (2011)117 Ca-19 + CEA + 
TIMP-1
173 70 120 71% 89% -
Capello et al. (2017)118 TIMP1 + LRG1 
+ Ca19-9 
73 - 60 0.849% 0.633% 0.949
Capello et al. (2017)118 TIMP1 + LRG1 
+ Ca19-9
73 74 - 0.452% 0.541% 0.890
Chan et al. (2014)119 Ca19-9 + Ca125 
+ LAMC2
139 65 10 82% 74%% 0.870
Makawita et al. (2013)115 CA19-9 + REG1B 82 41 92 - - 0.875
Makawita et al. (2013)115 CA19-9 + SYNC 
+ REG1B
82 41 92 - - 0.873
Makawita et al. (2013)115 CA19-9 + AGR2 
+ REG1B
82 41 92 - - 0.869
BTC, biliary tract cancer; PDAC, pancreatic ductal adenocarcinoma.
2. Bile and biliary brush biomarkers
Patients with an indeterminate stricture on cross-sectional 
imaging are typically referred for an ERCP and biliary brushing 
with or without endobilary biopsy to obtain tissue for diagnosis, 
with or without therapeutic stenting28. Although these techniques 
do not compromise resection margins in potentially resectable 
cases, sensitivity remains low (9–57%) and patients frequently 
have to undergo multiple procedures to obtain a diagnosis28–30. 
Bile can be easily obtained at the time of ERCP and, owing to 
its proximity to the tumour, is a potentially important source of 
diagnostic biomarkers in these cancers (Table 6). Unfortunately, 
owing to the invasiveness of ERCP, the role of these biomarkers is 
limited to diagnosis rather than screening or surveillance in these 
tumours.
3. Urinary biomarkers
Urine provides a very easy and acceptable source for biomarker 
analysis. In BTC, a 42-peptide panel (consisting mostly of frag-
ments of interstitial collagens) correctly identified 35 of 42 BTC 
patients with a sensitivity of 83% and a specificity of 79%42. In 
PDAC, the three-biomarker panel (LYVE-1, REG1A and TFF1) 
has been validated in a multi-centre cohort of 371 samples. When 
comparing PDAC stage I–IIA (resectable disease) with healthy 
urines, the panel achieved AUCs of 0.97 (95% confidence interval 
of 0.93–1.00). The performance of the urine biomarker panel in dis-
criminating PDAC stage I–IIA was superior to the performance of 
serum CA19-9 (P=0.006)43 (Table 7).
4. Symptoms and cancer decision support tools
Recently, pre-diagnostic symptom profiles have been investi-
gated as an alternative way of detecting hepato-pancreato-biliary 
(HPB) cancers at an early stage8,9,16,44. It is now recognised that the 
onset of PDAC and BTC is heralded by a collection of gastroin-
testinal and constitutional symptoms45. Although overlap occurs 
with other benign and malignant conditions, certain symptoms 
such as back pain, lethargy and new-onset diabetes have been 
identified as particularly suggestive of PDAC. Commonly 
performed blood tests such as liver function tests, glucose and 
haemoglobin also typically become abnormal in the months 
preceding diagnosis46. Therefore, cancer decision support tools 
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Table 4. Genetic and epigenetic alterations in circulating cell-free DNA pancreatic ductal adenocarcinoma and biliary 
tract cancer, 2013–2017.
Author (year) Target PDAC 
or BTC
Cancer, 
number
Benign 
lesions, 
number
Healthy 
volunteers, 
number
Detected Sensitivity Specificity
Takai et al. (2016)138 K-ras PDAC 107 (non-
operable)
- - 59% - -
Takai et al. (2015)124 cfDNA PDAC 48 29%  
Hadano et al. (2016)139 K-ras PDAC 105 - 20 31% - -
Zill et al. (2015)140 K-ras, TP53, 
APC, FBXW7, 
SMAD4
PDAC 26 - - - 92.3% 100%
Earl et al. (2015)135 K-ras PDAC 31 - - 26% - -
Kinusaga et al. (2015)123 G12V, G12D, 
and G12R in 
codon 12 of 
K-ras gene
PDAC 141 20 20 62% - -
Sausen et al. (2015)125 cfDNA PDAC 77 - - 43% - -
Wu et al. (2014)128 K-ras PDAC 24 - 25 72% - -
BTC, biliary tract cancer; PDAC, pancreatic ductal adenocarcinoma.
Table 5. Epigenetics: circulating non-coding RNA and DNA methylation markers in pancreatic ductal adenocarcinoma/biliary tract 
cancer, 2013–2017.
Author (year) MicroRNA Biliary 
tract 
cancer, 
number
Pancreatic 
ductal 
adenocarcinoma, 
number
Benign 
lesions, 
number
Healthy 
volunteers, 
number
Sensitivity Specificity Area 
under 
the 
curve
Circulating non-coding RNA
Kishimoto et al. (2013)141 MiR-21 (↑) 94 
94
- 
-
- 
23
50 
-
85% 
72.3%
100% 
91.3%
0.93 
0.83
Wang et al. (2013)142 miR-27a-3p + 
CA19-9(↑)
- 129 103 60 85.3% 81.6% 0.886
Kawaguchi et al. (2013)143 miR-221 (↑), 
miR-375 (↓)
- 47 - 30 - - 0.762
Zhao et al. (2013)144 miR-192 (↑) - 70 - 40 76% 55% 0.63
Carleson et al. (2013)145 MiR-375 (↑) - 48 47 - - - 0.72
Que et al. (2013)146 miR-17-5p (↑) 
miR-21 (↑), 
- 22 12 8 - - 0.887 
0.897
Schultz et al. (2014)147 Index I + CA19-9 
Index II + CA19-9
- 409 25 312 85% 
85%
88% 
86%
0.93 
0.92
Silakit et al. (2014)148 MiR-192 (↑) 11 - - 9 74% 72% 0.803
Lin et al. (2015)149 MiR-492 (↑) 
MiR-663a (↑)
- 49 - 27 75% 
85%
70% 
80%
0.787 
0.870
Chen et al. (2014)150 miR-182 (↑) - 109 38 50 64.1% 82.6% 0.775
Wang et al. (2015)151 MiR-150 (↑) 15 - - 15 80% 58% 0.764
Ganepola et al. (2015)152 miR-22 (↑), 
miR-642b (↑) 
miR-885-5p (↑)
- 11 - 11 91% 91% 0.970
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Author (year) MicroRNA Biliary 
tract 
cancer, 
number
Pancreatic 
ductal 
adenocarcinoma, 
number
Benign 
lesions, 
number
Healthy 
volunteers, 
number
Sensitivity Specificity Area 
under 
the 
curve
Voigtlander et al. (2015)153 
(serum)
MiR-1281 (↑) 
MiR-126 (↑) 
MiR-26a (↑) 
MiR-30b (↑) 
MiR-122 (↑)
31 - 40 - 55% 
68% 
52% 
52% 
32%
90% 
93% 
93% 
88% 
90%
0.83 
0.87 
0.78 
0.78 
0.65
Voigtlander et al. (2015)153 
(bile)
miR-412 (↑) 
miR-640 (↑) 
miR-1537 (↑) 
miR-3189 (↑)
31 - 53 - 50% 
50% 
67% 
67%
89% 
92% 
90% 
89%
0.81 
0.81 
0.78 
0.80
Abue et al. (2015)154 miR-21 (↑), 
miR-483-3p (↑)
- 32 12 30 - - 0.790 
0.754
Salter et al. (2015)155 miR-196a (↑), 
miR-196b (↑)
- 19 10 10 100% 90% 0.99
Kojima et al. (2015)156 miR-6075, 
miR-4294, 
miR-6880-5p, 
miR-6799-5p, 
miR-125a-3p, 
miR-4530, 
miR-6836-3p, 
miR-4476
98 100 21 150 80.3% 97.6% 0.953
Xu et al. (2015)157 miR-486-5p (↑) 
miR-938 (↑)
- 156 142 65 - - 0.861 
0.693
Madhaven et al. (2015)158 PaCIC + miRNA 
serum-exosome 
marker panel
- - - - 100% 80% -
Komatsu et al. (2015)159 miR-223 (↑) - 71 - 67 62% 94.1% 0.834
Alemar et al. (2016)160 MiR-21 (↑) 
MiR-34a (↑)
- 24 - 10 - - 0.889 
0.865
Wu et al. (2016)161 MiR-150 (↓) 30 30 28 50 - - -
Bernuzzi et al. (2016)162 MiR-483-5p(↑) 
MiR-194(↑)
40 40 70 40 - - 0.77 
0.74
Kim et al. (2016)163 mRNA – CDH3 (↑) 
mRNA –IGF2BP3(↑) 
mRNA – HOXB7 (↑) 
mRNA – BIRC5 (↑)
- 21 14 - 57.1% 
76.2% 
71.4% 
76.2%
64.3% 
100% 
57.1% 
64.3%
0.776 
0.476 
0.898 
0.818
Duell et al. (2017)164 MiR-10a (↑) 
MiR-10b (↑) 
MiR-21-5p (↑) 
MiR-30c (↑) 
MiR-155 (↑) 
MiR-212 (↑)
- 225 - 225 - - 0.66 
0.68 
0.64 
0.71 
0.64 
0.64
DNA hypermethylation
Branchi et al. (2016)165 SHOX2/SEPT9 20 - - 100 0.45% 0.99% 0.752
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Table 6. Bile and biliary brush biomarkers for pancreatic and biliary tract cancer.
Author (year) Biomarker Pancreatic ductal 
adenocarcinoma, 
number
Biliary tract 
cancer, 
number
Benign 
lesions, 
number
Healthy 
controls, 
number
Bile or 
biliary 
brush
Sensitivity Specificity Area 
under 
the 
curve
Single biomarkers
Dhar et al. (2013)166 M2-PK - 88 79 17 Bile 90.3% 84.3% -
Navaneethan  
et al. (2015)167
M2-PK - - - - Bile 52.9% 94.1% 0.77
Keane (2017)168 MCM5 24 17 47 Biliary 
brush 
55.6% 77.8% 0.79
Danese et al. 
(2014)169
MUC5AC - 20 20 - Serum 
Bile 
- - 0.94 
0.99
Farina et al. 
(2014)170
CEAM6 23 6 12 - Bile 93% 83% 0.92
Budzynska et al. 
(2013)171
NGAL 6 16 18 - Bile 77% 72% 0.74
Jiao et al. (2014)96 Nucleosides 202 
(gallbladder 
cancer)
203 205 Bile 95.3% 96.4% -
Ince et al. (2014)93 CE 41 25 129 - Bile 57.3% 68.2% 0.516
Ince et al. (2014)93 CA 19-9 41 25 129 - Bile 74.0% 34.1% 0.616
Ince et al. (2014)93 VEGFR3 41 25 129 - Bile 56.2% 79.1% 0.663
Ince et al. (2014)93 Total antioxidant 
capacity
41 25 129 - Bile 65.6% 50.4% 0.581
Abdel-Razik et al. 
(2016)114
IGF-1 25 18 62 - Bile 91.4% 89.5% 0.943
Abdel-Razik et al. 
(2016)114
VEGF 25 18 62 - Bile 90.3% 84.9% 0.915
Kim et al. (2016)163 mRNA – CDH3 (↑) 
mRNA –IGF2BP3(↑) 
mRNA – HOXB7 (↑) 
mRNA – BIRC5 (↑)
- 21 14 - Biliary 
brush
57.1% 
76.2% 
71.4% 
76.2%
64.3% 
100% 
57.1% 
64.3%
0.776 
0.476 
0.898 
0.818
Table 7. Summary of urine protein biomarkers for pancreatic and biliary tract cancer, 2013–2017.
Author (year) Biomarker/ 
Combination 
(urine)
Pancreatic ductal 
adenocarcinoma, 
number
Biliary tract 
cancer, 
number
Benign 
cancer/ 
Chronic 
pancreatitis, 
number
Healthy 
volunteers, 
number
Sensitivity Specificity Area 
under 
the 
curve
Single biomarker
Roy et al. (2014)172 MMP2 51 - - 60 70% 85% -
Roy et al. (2014)172 TIMP-1 51 - - 60 90% 70% -
Jiao et al. (2014)96 Nucleosides - 202 
(gallbladder 
cancer)
203 205 89.4% 97.1% -
Metzger et al. (2013)42 Urine Proteomic 
analysis
- 42 81 - 83% 79% 0.87
Biomarker combinations
Radon et al. (2015)43 LYVE-1 + 
REG1A + TFF1
192 - - 87 - - 0.89
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have been produced from combinations of symptoms and risk 
factors. In the UK, they have been introduced into general prac-
tices in 15 cancer networks to date8, and their utility is currently 
being audited47. Modification to existing tools to enhance their 
diagnostic accuracy can be expected in the future.
Endoscopy
1. Endoscopic ultrasonography
If there is a mass lesion on cross-sectional imaging, endo-
scopic ultrasonography with fine-needle aspiration (EUS-FNA) 
provides an alternative method for visualising and sampling 
the extra-hepatic biliary tree, pancreas, gallbladder or peri-hilar 
lymph nodes. EUS-FNA has a diagnostic accuracy for PDAC of 
between 65% and 96%48,49. In BTC, a single-centre study 
reported a sensitivity of 73%, which was significantly better in 
distal compared with proximal tumours (81% versus 59% respec-
tively, P=0.04)50. Recently, developed fine core biopsy needles 
appear to have improved diagnostic accuracy over traditional 
FNA needles, but randomised trials are awaited49,51,52. Rapid onsite 
examination by a cytopathologist is used in some centres, 
particularly in North America, and has been shown to improve the 
yield of EUS-FNA in individual centres53,54 but this trend has not 
been borne out in recent randomised controlled trials55.
To improve the diagnostic accuracy of EUS, it can also be com-
bined with novel adjuncts such as contrast agents (SonoVue®), 
transient elastography (TE) or confocal laser endomicroscopy 
(CLE). TE allows the measurement of the tissue firmness, which 
tends to be increased in malignant tissue. In a recent single- 
centre study from the UK, quantitative strain measurements were 
found to have high sensitivity but low specificity for the detec-
tion of PDAC56. The technology to perform the techniques is 
available on most modern EUS machines and adds little time to the 
overall procedure time. The technique can be performed equally 
well by endosonographers with limited experience57,58 and is par-
ticularly advantageous in cases where the diagnosis remains uncer-
tain after standard EUS has been performed59. Contrast-enhanced 
EUS is performed with agents such as SonoVue® and allows vis-
ualisation of the early arterial phase and late parenchymal phase 
enhancement of the pancreas. Pancreatic tumours are generally 
hypovascular compared with the surrounding parenchyma60,61. 
Dynamic contrast EUS is a relatively novel method that allows 
the non-invasive quantification of the tumour perfusion compared 
with the pancreatic parenchyma by using software that is now 
built into a number of EUS scanners. The use of this technology is 
evolving but is expected to be most applicable when predicting 
tumour response to chemotherapeutic agents, particularly new 
drugs against vascular angioneogenesis62,63.
Recently, a needle-based confocal endomicroscope has also been 
developed which can be passed through a 19G FNA needle to 
assess indeterminate masses, cysts or lymph nodes. Malignancy 
in the hepatobilary tract is identified by the presence of irregular 
vessels, vascular leakage and large dark clumps (Figure 1)64. In a 
recent study of 25 patients with indeterminate pancreatic masses 
referred for EUS-FNA, needle-based CLE was shown to be a safe 
and feasible technique65.
Figure 1. Novel diagnostic adjuncts to ERCP and EUS. (a) 
Cholangioscopic view of a malignant hilar stricture with visualisation 
of the ulcerated, friable biliary mucosa via the Spyglass 
cholangioscope system (Boston Scientific Corp, Massachusetts, 
USA). (b) Confocal endomicroscopic image of pancreatic cancer, 
showing characteristic black clumps. Image was obtained using the 
Cellvizio AQ-Flex® probe which was introduced to the tumour via 
19G FNA needle at the time of EUS.
2. Endoscopic retrograde cholangiopancreatography
ERCP is typically undertaken when imaging demonstrates an 
indeterminate biliary stricture and tissue acquisition is required 
for cytological or histological assessment. Biliary brush cytol-
ogy and endobiliary biopsy have a sensitivity for malignancy 
of 9–57%29,30,66,67. Most HPB tumours exhibit chromosomal 
aneuploidy68; therefore, in some centres, fluorescence in situ 
hybridisation and digital image analysis are used to assess for 
the presence of DNA abnormalities in brush cytology30,69. 
Although these techniques have been adopted by only a few 
centres, the presence of polysomy is highly suggestive of BTC30,69. 
Poor diagnostic accuracy in biliary brush and endobiliary samples 
has been attributed to their being non-targeted samples 
obtained with only fluoroscopic guidance70. The single- 
operator cholangioscopy system (SpyGlass, Boston Scientific 
Corporation, Natick, MA, USA) introduced in 2006 and now 
superseded by the SpyGlass DS system enables intrabiliary biop-
sies under direct vision via small disposable forceps (Figure 1). 
In a recent systematic review, the sensitivity and specificity of 
cholangioscopy-guided biopsies in the diagnosis of malignant 
biliary strictures were 60.1% and 98.0%, respectively71. Higher 
sensitivities are observed for intrinsic biliary malignancy compared 
with extrinsic compressing tumours72. Several techniques have 
been employed to augment the visualised mucosa during cholan-
gioscopy, including chromendoscopy with methylene blue73–75, 
narrow-band imaging76,77 and autofluorescence78.
During ERCP, a “CholangioFlex” confocal probe (Mauna Kea 
Technologies, Paris, France) can be placed down the working 
channel of a cholangioscope or duodenoscope to obtain real-time 
CLE images, which are akin to standard histology (Figure 1). If 
the images obtained from a point on the biliary mucosa contain 
dark areas, this is highly suggestive of malignancy79,80. The diag-
nostic accuracy of probe-based CLE was recently validated in 
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a prospective multi-centre international study with 112 patients 
(71 with malignant lesions). Tissue sampling alone had a sensitiv-
ity, specificity and diagnostic accuracy of 56%, 100% and 72%, 
respectively. In comparison, ERCP with probe-based CLE had a 
sensitivity, specificity and diagnostic accuracy of 89%, 71% and 
82%, respectively. Diagnostic accuracy increased to 88% when 
probe-based CLE and tissue sampling results were combined81. 
CLE is also feasible in the pancreatic duct during pancreati-
coscopy but, owing to concerns over pancreatitis, is rarely used. 
In a case report by Meining et al., the presence of a main duct- 
intraductal papillary mucinous neoplasia was confirmed by clear 
views of typical finger-like projections82. Intraductal ultrasound in 
small studies has also been shown to have a diagnostic accuracy of 
up to 90%83.
Conclusions
Currently, the most widely used tumour marker in pancreatico-
biliary malignancy is CA19-9. However, its use is limited by its 
elevation in a number of other benign and malignant condi-
tions. Furthermore, it is not produced in approximately 7% of the 
population who are Lewis antigen–negative and is often undetect-
able when tumours are small. Over the last few years, a number 
of very promising biomarker panels have been identified which 
can detect tumours at an early stage when curative intervention 
could be possible. These markers are subject to ongoing validation 
studies but appear likely to be implemented into screening pro-
grammes, particularly for high-risk groups, in the near future. 
Novel endoscopic techniques such as per-oral cholangioscopy and 
confocal endomicroscopy can enhance the diagnostic accuracy of 
standard techniques and are increasingly available in large-volume 
centres worldwide.
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